Jim Simons’s Sunshine Biopharma SBFM Stock Holding History

Jim Simons’s Portfolio SBFM Stock Details SBFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,570	Closed	-$83K	–	3689
2025 Q3	$83K	Buy	5,570 +161	+3%	+$2.39K	﹤0.01%	3276
2025 Q2	$77.9K	Buy	+5,409	New	+$79K	﹤0.01%	3336
2024 Q2	–	Sell	-231	Closed	-$279K	–	3901
2024 Q1	$279K	Buy	231 +228	+7,600%	+$670K	﹤0.01%	3116
2023 Q4	$18K	Buy	+3	New	+$17.1K	﹤0.01%	3590

Other funds holding SBFM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SAG

SageView Advisory Group Newport Beach, California $3.05B AUM 18.61% 1-Year Est. Return

Jim Simons's SBFM Position: Q4 2025 in Review

Jim Simons sold out of Sunshine Biopharma (SBFM) in Q4 2025, closing a stake of 5,570 shares — an estimated $83K sold.

Jim Simons first reported a position in SBFM in Q4 2023 and held it in 4 quarters. The position peaked at $279K in Q1 2024. 9 funds tracked by Wall St. Rank hold SBFM as of Q4 2025.

Jim Simons reported no remaining Sunshine Biopharma position as of Q4 2025 after selling out during the quarter.
Jim Simons sold 5,570 Sunshine Biopharma shares in Q4 2025, an estimated $83K.
Jim Simons first reported a position in Sunshine Biopharma in Q4 2023 and held it in 4 quarters.
Jim Simons's Sunshine Biopharma position peaked at $279K in Q1 2024.
9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.